Cartron, G. & Trotman, J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica 107, 7–18 (2022).
Kastenschmidt, J. M. et al. A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment. Cell Stem Cell 31, 410–420.e414 (2024).
Couronné, L. et al. From hepatitis C virus infection to B-cell lymphoma. Ann. Oncol. 29, 92–100 (2018).
Defrancesco, I. et al. Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. Am. J. Hematol. 96, E210–e214 (2021).
Li, M. et al. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. Int. J. Cancer 147, 2199–2209 (2020).
Lemaitre, M. et al. Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. J. Infect. 80, 219–224 (2020).
Ren, W. et al. Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. Blood Adv. 6, 2731–2744 (2022).
Zhou, X. et al. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma. BMC Cancer 19, 477 (2019).
Russler-Germain, D. A. et al. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: alliance A151303. Blood Adv. 7, 5524–5539 (2023).
Li, X. et al. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41, 1835–1837 (2023).
Wang, N. et al. Hepatitis B virus-associated follicular lymphoma presents T-cell inflamed phenotype and response to lenalidomide. Cancer Commun. 42, 170–174 (2022).
Andor, N. et al. Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. Blood 133, 1119–1129 (2019).
Sarkozy, C. et al. Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma. Cancer Cell 42, 1003–1017.e1006 (2024).
Krausgruber, T. et al. Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. Immunity 56, 289–306.e287 (2023).
Han, G. et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 3, 428–443 (2022).
Kan, G. et al. Dual inhibition of DKC1 and MEK1/2 synergistically restrains the growth of colorectal cancer cells. Adv. Sci. 8, 2004344 (2021).
Shi, Y. & Zheng, M. Hepatitis B virus persistence and reactivation. BMJ 370, m2200 (2020).
Planchais, C. et al. HIV-1 treatment timing shapes the human intestinal memory B-cell repertoire to commensal bacteria. Nat. Commun. 14, 6326 (2023).
Deng, Y. et al. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Nat. Commun. 13, 4739 (2022).
Wang, X. et al. Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk. Nat. Commun. 13, 6772 (2022).
Correia, C. et al. Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era. Blood Cancer J. 13, 81 (2023).
Schroers-Martin, J. G. et al. Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors. Cancer Discov. 13, 1310–1323 (2023).
Radtke, A. J. & Roschewski, M. The follicular lymphoma tumor microenvironment at single-cell and spatial resolution. Blood 143, 1069–1079 (2024).
Yuan, L. et al. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma. Cancer Immunol. Immunother. 71, 399–415 (2022).
He, T. et al. CXCL6 reshapes lipid metabolism and induces neutrophil extracellular trap formation in cholangiocarcinoma progression and immunotherapy resistance. Adv. Sci. 12, e2503009 (2025).
Balan, S. & Bhardwaj, N. Cross-presentation of tumor antigens is ruled by synaptic transfer of vesicles among dendritic cell subsets. Cancer Cell 37, 751–753 (2020).
Weiss, S. A. et al. Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control. Nat. Immunol. 25, 1871–1883 (2024).
Jørgensen, A. S. et al. The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus. Cell. Mol. Life Sci. 78, 6963–6978 (2021).
Cheng, C. L. et al. Hepatitis B surface antigen positivity is associated with progression of disease within 24 months in follicular lymphoma. J. Cancer Res. Clin. Oncol. 148, 1211–1222 (2022).
Qin, W. et al. Genomic and transcriptomic characterization reveals B-cell hyperactivation and immune evasion in hepatitis B virus-associated diffuse large B-cell lymphoma. Clin. Transl. Med. 13, e1293 (2023).
Jerby-Arnon, L. & Regev, A. DIALOGUE maps multicellular programs in tissue from single-cell or spatial transcriptomics data. Nat. Biotechnol. 40, 1467–1477 (2022).
Cooper, L. et al. Type I interferons induce an epigenetically distinct memory B cell subset in chronic viral infection. Immunity https://doi.org/10.1016/j.immuni.2024.03.016 (2024).
Tolar, P. & Pierce, S. K. Unveiling the B cell receptor structure. Science 377, 819–820 (2022).
Kalmbach, S. et al. Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms. Leukemia 37, 2058–2065 (2023).
Wang, H., Liu, B. & Wei, J. Beta2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy. Cancer Lett. 517, 96–104 (2021).
Han, J. M. & Jung, H. J. Cyclophilin A/CD147 interaction: a promising target for anticancer therapy. Int. J. Mol. Sci. 23, https://doi.org/10.3390/ijms23169341 (2022).
Suleman, A. et al. Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario. Br. J. Haematol. 202, 1104–1118 (2023).
Zander, R. & Cui, W. Exhausted CD8(+) T cells face a developmental fork in the road. Trends Immunol. 44, 276–286 (2023).
Montali, I. et al. Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B. J. Hepatol. 79, 50–60 (2023).
Wei, J. et al. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models. Sci. Transl. Med. 14, eabn1082 (2022).
Elfrink, S. et al. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. Blood Adv. 6, 2254–2266 (2022).
Ju, H. et al. A regulatory polymorphism at position -309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression. Neoplasia 11, 1340–1347 (2009).
Stilgenbauer, S. et al. Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. Leukemia 33, 2531–2535 (2019).
Roddie, C. et al. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma. Blood 141, 2470–2482 (2023).
Gillette, M. A. et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 182, 200–225.e235 (2020).
Béguelin, W. et al. Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response. Cancer Cell 37, 655–673.e611 (2020).
Martínez-Riaño, A. et al. Long-term retention of antigens in germinal centers is controlled by the spatial organization of the follicular dendritic cell network. Nat. Immunol. 24, 1281–1294 (2023).
Wang, C. et al. The relationship between hepatitis B virus serum DNA, RNA and quantitative hepatitis B surface antigen, and the predictive value for mother-to-child transmission: an observational cohort study. BJOG 129, 241–247 (2022).
Yuen, M. F. et al. Hepatitis B virus infection. Nat. Rev. Dis. Primers 4, 18035 (2018).
Sun, Y. et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clin. Gastroenterol. Hepatol. 18, 2582–2591.e2586 (2020).
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398, (2017).